Is Coherus BioSciences, Inc. overvalued or undervalued?

As of 6 May 2021, the valuation grade for Coherus BioSciences, Inc. moved from fair to risky, indicating a significant deterioration in its financial health. The company is currently assessed as overvalued given its negative performance metrics, including a Price to Book Value of -0.52 and an EV to EBITDA ratio of -3.01. Additionally, the Return on Capital Employed (ROCE) stands at a staggering -350.73%, highlighting the company's struggles to generate returns on its investments.
In comparison to its peers, Coherus BioSciences, Inc. shows a P/E ratio of -0.8576, while Procaps Group SA, categorized as very attractive, boasts a P/E ratio of 605.2206, illustrating a stark contrast in valuation. Other risky peers like ARS Pharmaceuticals, Inc. and Liquidia Corp. also reflect negative valuations, with P/E ratios of -92.4143 and -8.6024, respectively. The company's recent stock performance has been dismal, with a year-to-date return of -47.34%, significantly underperforming the S&P 500's 2.44% return, reinforcing the notion that it is currently overvalued.